Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice

K. Zhang, J. Gan, B. Wang, W. Lei, D. Zhen, J. Yang, N. Wang, C. Wen, X. Gao, X. Li, A. Xu, X. Liu, Y. Li, F. Wu, Z. Lin

. 2025 ; 16 (1) : 1661. [pub] 20250215

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009869

Grantová podpora
81925004 China National Funds for Distinguished Young Scientists

Fibroblast growth factor 21 (FGF21), a metabolic hormone with pleiotropic effects, is beneficial for various cardiac disorders. However, FGF21's role in heart failure with preserved ejection fraction (HFpEF) remains unclear. Here, we show that elevated circulating FGF21 levels are negatively associated with cardiac diastolic function in patients with HFpEF. Global or adipose FGF21 deficiency exacerbates cardiac diastolic dysfunction and damage in high-fat diet (HFD) plus N[w]-nitro-L-arginine methyl ester (L-NAME)-induced HFpEF mice, whereas these effects are notably reversed by FGF21 replenishment. Mechanistically, FGF21 enhances the production of adiponectin (APN), which in turn indirectly acts on cardiomyocytes, or FGF21 directly targets cardiomyocytes, to negatively regulate pyruvate dehydrogenase kinase 4 (PDK4) production by activating PI3K/AKT signals, then promoting mitochondrial bioenergetics. Additionally, APN deletion strikingly abrogates FGF21's protective effects against HFpEF, while genetic PDK4 inactivation markedly mitigates HFpEF in mice. Thus, FGF21 protects against HFpEF via fine-tuning the multiorgan crosstalk among the adipose, liver, and heart.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009869
003      
CZ-PrNML
005      
20250429135344.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41467-025-56885-9 $2 doi
035    __
$a (PubMed)39955281
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Zhang, Ke $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
245    10
$a FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice / $c K. Zhang, J. Gan, B. Wang, W. Lei, D. Zhen, J. Yang, N. Wang, C. Wen, X. Gao, X. Li, A. Xu, X. Liu, Y. Li, F. Wu, Z. Lin
520    9_
$a Fibroblast growth factor 21 (FGF21), a metabolic hormone with pleiotropic effects, is beneficial for various cardiac disorders. However, FGF21's role in heart failure with preserved ejection fraction (HFpEF) remains unclear. Here, we show that elevated circulating FGF21 levels are negatively associated with cardiac diastolic function in patients with HFpEF. Global or adipose FGF21 deficiency exacerbates cardiac diastolic dysfunction and damage in high-fat diet (HFD) plus N[w]-nitro-L-arginine methyl ester (L-NAME)-induced HFpEF mice, whereas these effects are notably reversed by FGF21 replenishment. Mechanistically, FGF21 enhances the production of adiponectin (APN), which in turn indirectly acts on cardiomyocytes, or FGF21 directly targets cardiomyocytes, to negatively regulate pyruvate dehydrogenase kinase 4 (PDK4) production by activating PI3K/AKT signals, then promoting mitochondrial bioenergetics. Additionally, APN deletion strikingly abrogates FGF21's protective effects against HFpEF, while genetic PDK4 inactivation markedly mitigates HFpEF in mice. Thus, FGF21 protects against HFpEF via fine-tuning the multiorgan crosstalk among the adipose, liver, and heart.
650    _2
$a zvířata $7 D000818
650    12
$a fibroblastové růstové faktory $x metabolismus $x genetika $7 D005346
650    12
$a energetický metabolismus $x účinky léků $7 D004734
650    _2
$a myši $7 D051379
650    12
$a kardiomyocyty $x metabolismus $x účinky léků $7 D032383
650    12
$a srdeční selhání $x metabolismus $x prevence a kontrola $x genetika $7 D006333
650    _2
$a mužské pohlaví $7 D008297
650    12
$a srdeční mitochondrie $x metabolismus $x účinky léků $7 D008929
650    _2
$a lidé $7 D006801
650    12
$a adiponektin $x metabolismus $x genetika $7 D052242
650    12
$a PDH-kinasa $x metabolismus $x genetika $7 D000081382
650    12
$a dieta s vysokým obsahem tuků $x škodlivé účinky $7 D059305
650    _2
$a myši knockoutované $7 D018345
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a tepový objem $x účinky léků $7 D013318
650    _2
$a protoonkogenní proteiny c-akt $x metabolismus $7 D051057
650    _2
$a signální transdukce $7 D015398
650    _2
$a fosfatidylinositol-3-kinasy $x metabolismus $7 D019869
650    _2
$a tuková tkáň $x metabolismus $7 D000273
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gan, Jing $u The Affiliated Dongguan Songshan Lake Center Hospital, The Innovative Center of Cardiometabolic Disease, Guangdong Medical University, Dongguan, China
700    1_
$a Wang, Baile $u State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China $1 https://orcid.org/0000000280802964
700    1_
$a Lei, Wei $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China $u Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
700    1_
$a Zhen, Dong $u The Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
700    1_
$a Yang, Jie $u Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Anzhen Hospital of Capital Medical University, Beijing, China
700    1_
$a Wang, Ningrui $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
700    1_
$a Wen, Congcong $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
700    1_
$a Gao, Xiaotang $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
700    1_
$a Li, Xiaokun $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China $1 https://orcid.org/0000000265566262
700    1_
$a Xu, Aimin $u State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China $1 https://orcid.org/000000020668033X
700    1_
$a Liu, Xinguang $u Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, Guangdong Medical University, Dongguan, China. liuxg@gdmu.edu.cn
700    1_
$a Li, Yulin $u Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Anzhen Hospital of Capital Medical University, Beijing, China. lyllyl_1111@163.com $1 https://orcid.org/0000000179090763
700    1_
$a Wu, Fan $u The Affiliated Dongguan Songshan Lake Center Hospital, The Innovative Center of Cardiometabolic Disease, Guangdong Medical University, Dongguan, China. zflwf@126.com $1 https://orcid.org/0000000301363084
700    1_
$a Lin, Zhuofeng $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China. zlin@gdmu.edu.cn $u The Affiliated Dongguan Songshan Lake Center Hospital, The Innovative Center of Cardiometabolic Disease, Guangdong Medical University, Dongguan, China. zlin@gdmu.edu.cn
773    0_
$w MED00184850 $t Nature communications $x 2041-1723 $g Roč. 16, č. 1 (2025), s. 1661
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39955281 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135340 $b ABA008
999    __
$a ok $b bmc $g 2311325 $s 1246950
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 16 $c 1 $d 1661 $e 20250215 $i 2041-1723 $m Nature communications $n Nat Commun $x MED00184850
GRA    __
$a 81925004 $p China National Funds for Distinguished Young Scientists
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace